Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: J Immunol. 2016 Mar 4;196(8):3354–3363. doi: 10.4049/jimmunol.1502687

Table II. Summary of AdHu5 processing constructs.

Vector Promoter Insert P:I Used at
(iu/mouse)
Ad-I8V HCMV β-gal497-504 17 1×108
Ad-D8V HCMV β-gal96-103 23 1×108
Ad-M45 HCMV M45985-993 25 1×108
Ad-7aa-I8V HCMV β-gal490-504 20 1×108
Ad-10aa-I8V HCMV β-gal487-504 60 1×108
Ad-10aa-I8V-10aa HCMV β-gal487-514 42 1×108
Ad-I8V-10aa HCMV β-gal497-514 28 1×108
Ad-I8V-D8V
(Ad-ICD) 		HCMV β-gal497-504-
GGGCCCGGG –
β-gal96-103 		22 1×108
Ad-D8V-I8V
(Ad-DAI) 		HCMV β-gal96-103 -
GGGCCCGGG –
β-gal497-504 		21 1×108

AdHu5 replication-deficient vectors used with their varying inserts are shown (all have a human IE CMV promoter). P:I ratios (particle number to infectivity) are shown alongside the viral titre in infectious units for which the virus was immunised into a single mouse.